ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 6, 2025, to report their compliance with the Securities Exchange Act of 1934 and confirmed they will file annual reports under Form 20-F. This filing does not contain significant events or quantitative data beyond the formal submission details.